<?xml version='1.0' encoding='utf-8'?>
<document id="19895663"><sentence text="The alpha(2) adrenoceptor antagonist idazoxan alleviates L-DOPA-induced dyskinesia by reduction of striatal dopamine levels: an in vivo microdialysis study in 6-hydroxydopamine-lesioned rats."><entity charOffset="37-45" id="DDI-PubMed.19895663.s1.e0" text="idazoxan" /><entity charOffset="108-116" id="DDI-PubMed.19895663.s1.e1" text="dopamine" /><entity charOffset="159-176" id="DDI-PubMed.19895663.s1.e2" text="6-hydroxydopamine" /><pair ddi="false" e1="DDI-PubMed.19895663.s1.e0" e2="DDI-PubMed.19895663.s1.e0" /><pair ddi="false" e1="DDI-PubMed.19895663.s1.e0" e2="DDI-PubMed.19895663.s1.e1" /><pair ddi="false" e1="DDI-PubMed.19895663.s1.e0" e2="DDI-PubMed.19895663.s1.e2" /><pair ddi="false" e1="DDI-PubMed.19895663.s1.e1" e2="DDI-PubMed.19895663.s1.e1" /><pair ddi="false" e1="DDI-PubMed.19895663.s1.e1" e2="DDI-PubMed.19895663.s1.e2" /></sentence><sentence text="L-DOPA-induced dyskinesia is characterised by debilitating involuntary movement, which limits quality of life in patients suffering from Parkinson's disease" /><sentence text=" Here, we investigate effects of the a2 adrenoceptor antagonist idazoxan on L-DOPA-induced dyskinesia as well as on alterations of extracellular L-DOPA and dopamine (DA) levels in the striatum in dyskinetic rats"><entity charOffset="64-72" id="DDI-PubMed.19895663.s3.e0" text="idazoxan" /><entity charOffset="145-151" id="DDI-PubMed.19895663.s3.e1" text="L-DOPA" /><entity charOffset="156-164" id="DDI-PubMed.19895663.s3.e2" text="dopamine" /><entity charOffset="166-168" id="DDI-PubMed.19895663.s3.e3" text="DA" /><pair ddi="false" e1="DDI-PubMed.19895663.s3.e0" e2="DDI-PubMed.19895663.s3.e0" /><pair ddi="false" e1="DDI-PubMed.19895663.s3.e0" e2="DDI-PubMed.19895663.s3.e1" /><pair ddi="false" e1="DDI-PubMed.19895663.s3.e0" e2="DDI-PubMed.19895663.s3.e2" /><pair ddi="false" e1="DDI-PubMed.19895663.s3.e0" e2="DDI-PubMed.19895663.s3.e3" /><pair ddi="false" e1="DDI-PubMed.19895663.s3.e1" e2="DDI-PubMed.19895663.s3.e1" /><pair ddi="false" e1="DDI-PubMed.19895663.s3.e1" e2="DDI-PubMed.19895663.s3.e2" /><pair ddi="false" e1="DDI-PubMed.19895663.s3.e1" e2="DDI-PubMed.19895663.s3.e3" /><pair ddi="false" e1="DDI-PubMed.19895663.s3.e2" e2="DDI-PubMed.19895663.s3.e2" /><pair ddi="false" e1="DDI-PubMed.19895663.s3.e2" e2="DDI-PubMed.19895663.s3.e3" /></sentence><sentence text=" Male Wistar rats were unilaterally lesioned with 6-hydroxydopamine and subsequently treated with L-DOPA/benserazide to induce stable dyskinetic movements"><entity charOffset="50-67" id="DDI-PubMed.19895663.s4.e0" text="6-hydroxydopamine" /><entity charOffset="98-104" id="DDI-PubMed.19895663.s4.e1" text="L-DOPA" /><entity charOffset="105-116" id="DDI-PubMed.19895663.s4.e2" text="benserazide" /><pair ddi="false" e1="DDI-PubMed.19895663.s4.e0" e2="DDI-PubMed.19895663.s4.e0" /><pair ddi="false" e1="DDI-PubMed.19895663.s4.e0" e2="DDI-PubMed.19895663.s4.e1" /><pair ddi="false" e1="DDI-PubMed.19895663.s4.e0" e2="DDI-PubMed.19895663.s4.e2" /><pair ddi="false" e1="DDI-PubMed.19895663.s4.e1" e2="DDI-PubMed.19895663.s4.e1" /><pair ddi="false" e1="DDI-PubMed.19895663.s4.e1" e2="DDI-PubMed.19895663.s4.e2" /></sentence><sentence text="Administration of idazoxan [(9 mg/kg, intraperitoneal (i"><entity charOffset="18-26" id="DDI-PubMed.19895663.s5.e0" text="idazoxan" /></sentence><sentence text="p" /><sentence text=")]significantly alleviated L-DOPA-induced dyskinesia, whereas idazoxan (3 mg/kg, i"><entity charOffset="62-70" id="DDI-PubMed.19895663.s7.e0" text="idazoxan" /></sentence><sentence text="p" /><sentence text=") did not affect dyskinetic behaviour" /><sentence text="Bilateral in vivo microdialysis revealed that idazoxan 9 mg/kg reduces extracellular peak L-DOPA levels in the lesioned and intact striatum as well as DA levels in the lesioned striatum"><entity charOffset="46-54" id="DDI-PubMed.19895663.s10.e0" text="idazoxan" /><entity charOffset="90-96" id="DDI-PubMed.19895663.s10.e1" text="L-DOPA" /><entity charOffset="151-156" id="DDI-PubMed.19895663.s10.e2" text="DA" /><pair ddi="false" e1="DDI-PubMed.19895663.s10.e0" e2="DDI-PubMed.19895663.s10.e0" /><pair ddi="false" e1="DDI-PubMed.19895663.s10.e0" e2="DDI-PubMed.19895663.s10.e1" /><pair ddi="false" e1="DDI-PubMed.19895663.s10.e0" e2="DDI-PubMed.19895663.s10.e2" /><pair ddi="false" e1="DDI-PubMed.19895663.s10.e1" e2="DDI-PubMed.19895663.s10.e1" /><pair ddi="false" e1="DDI-PubMed.19895663.s10.e1" e2="DDI-PubMed.19895663.s10.e2" /></sentence><sentence text=" In parallel, the exposure to idazoxan in the striatum was monitored"><entity charOffset="30-38" id="DDI-PubMed.19895663.s11.e0" text="idazoxan" /></sentence><sentence text="Furthermore, no idazoxan and L-DOPA drug-drug interaction was found in plasma, brain tissue and CSF"><entity charOffset="16-24" id="DDI-PubMed.19895663.s12.e0" text="idazoxan" /><entity charOffset="29-35" id="DDI-PubMed.19895663.s12.e1" text="L-DOPA" /><pair ddi="false" e1="DDI-PubMed.19895663.s12.e0" e2="DDI-PubMed.19895663.s12.e0" /><pair ddi="false" e1="DDI-PubMed.19895663.s12.e0" e2="DDI-PubMed.19895663.s12.e1" /></sentence><sentence text=" In conclusion, the decrease of L-DOPA-derived extracellular DA levels in the lesioned striatum significantly contributes to the anti-dyskinetic effect of idazoxan"><entity charOffset="155-163" id="DDI-PubMed.19895663.s13.e0" text="idazoxan" /><entity charOffset="61-68" id="DDI-PubMed.19895663.s13.e1" text="DA" /><pair ddi="false" e1="DDI-PubMed.19895663.s13.e1" e2="DDI-PubMed.19895663.s13.e1" /><pair ddi="false" e1="DDI-PubMed.19895663.s13.e1" e2="DDI-PubMed.19895663.s13.e0" /></sentence><sentence text="" /></document>